Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

被引:522
|
作者
Ehrmann, DA
Liljenquist, DR
Kasza, K
Azziz, R
Legro, RS
Ghazzi, MN
机构
[1] Univ Chicago, Endocrinol Sect, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Hlth Studies, Pritzker Sch Med, Chicago, IL 60637 USA
[3] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[4] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA 17033 USA
[5] Pfizer Pharmaceut Inc, Ann Arbor, MI 48105 USA
来源
关键词
D O I
10.1210/jc.2005-1329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) and the metabolic syndrome have many features in common and may share the same pathogenesis. Objective: This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS. Design: The clinical, hormonal, and oral glucose tolerance test results were analyzed in 394 PCOS women who were screened for participation in a multicenter trial to evaluate the effects of troglitazone on ovulation and hirsutism. Setting: A multicenter clinical trial is presented. Patients or Other Participants: The subjects were women with PCOS who had or lacked the metabolic syndrome. Main Outcome Measures: Waist circumference, fasting glucose, high-density lipoprotein cholesterol and triglyceride concentrations, and blood pressure were the main outcome measures. Results: Twenty-six (6.6%) subjects had diabetes; among the 368 nondiabetics, the prevalence for individual components comprising the metabolic syndrome were: waist circumference greater than 88 cm in 80%, high-density lipoprotein cholesterol less than 50 mg/dl in 66%, triglycerides greater than or equal to 150 mg/dl in 32%, blood pressure greater than or equal to 130/85 mm Hg in 21%, and fasting glucose concentrations greater than or equal to 110 mg/dl in 5%. Three or more of these individual criteria were present in 123 (33.4%) subjects overall. The prevalence of the metabolic syndrome did not differ significantly between racial/ethnic groups. The prevalence of the metabolic syndrome from lowest to highest quartile of free testosterone concentration was 19.8, 31.3, 46.9, and 35.0%, respectively [P=0.056 adjusted for body mass index (BMI)]. None of the 52 women with a BMI less than 27.0 kg/m(2) had the metabolic syndrome; those in the top BMI quartile were 13.7 times more likely (95% confidence interval, 5.7-33.0) to have the metabolic syndrome compared with those in the lowest quartile. Thirty-eight percent of those with the metabolic syndrome had impaired glucose tolerance compared with 19% without the metabolic syndrome (P<0.001). Conclusions: The metabolic syndrome and its individual components are common in PCOS, particularly among women with the highest insulin levels and BMI. Hyperinsulinemia is a likely common pathogenetic factor for both PCOS and the metabolic syndrome.
引用
收藏
页码:48 / 53
页数:6
相关论文
共 50 条
  • [21] Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions
    Bhattacharya, Sudhindra Mohan
    GYNECOLOGICAL ENDOCRINOLOGY, 2010, 26 (07) : 516 - 520
  • [22] Metabolic syndrome in women with polycystic ovary syndrome: Prevalence in cities in northeastern regions of Brazil
    Soares, Elvira M. M.
    Azevedo, George D.
    Maranhao, Tecia M. O.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (06) : 1027 - 1028
  • [23] Prevalence of Metabolic Disorders in Polycystic Ovary Syndrome
    Avelino da Silva, Damaris Esperque
    RBONE-REVISTA BRASILEIRA DE OBESIDADE NUTRICAO E EMAGRECIMENTO, 2013, 7 (41): : 105 - 114
  • [24] Predictors of depression in women with polycystic ovary syndrome
    Syed Haider Naqvi
    Ava Moore
    Kris Bevilacqua
    Sanam Lathief
    Joanne Williams
    Nighat Naqvi
    Lubna Pal
    Archives of Women's Mental Health, 2015, 18 : 95 - 101
  • [25] The polycystic ovary syndrome phenotype modulates prevalence of the metabolic syndrome
    Tan, S.
    Hahn, S.
    Sack, S.
    Benson, S.
    Elsenbruch, S.
    Schmidt, M.
    Kimmig, R.
    Erbel, R.
    Mann, K.
    Janssen, O. E.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2007, 115 : S19 - S19
  • [26] Predictors of depression in women with polycystic ovary syndrome
    Naqvi, Syed Haider
    Moore, Ava
    Bevilacqua, Kris
    Lathief, Sanam
    Williams, Joanne
    Naqvi, Nighat
    Pal, Lubna
    ARCHIVES OF WOMENS MENTAL HEALTH, 2015, 18 (01) : 95 - 101
  • [27] Predictors of Pregnancy in Women with Polycystic Ovary Syndrome
    Rausch, Mary E.
    Legro, Richard S.
    Barnhart, Huiman X.
    Schlaff, William D.
    Carr, Bruce R.
    Diamond, Michael P.
    Carson, Sandra A.
    Steinkampf, Michael P.
    McGovern, Peter G.
    Cataldo, Nicholas A.
    Gosman, Gabriella G.
    Nestler, John E.
    Giudice, Linda C.
    Leppert, Phyllis C.
    Myers, Evan R.
    Coutifaris, Christos
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (09): : 3458 - 3466
  • [28] Lipid ratios and obesity indices are effective predictors of metabolic syndrome in women with polycystic ovary syndrome
    Kaluzna, Malgorzata
    Czlapka-Matyasik, Magdalena
    Kompf, Pola
    Moczko, Jerzy
    Wachowiak-Ochmanska, Katarzyna
    Janicki, Adam
    Samarzewska, Karolina
    Ruchala, Marek
    Ziemnicka, Katarzyna
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [29] How prevalent is metabolic syndrome in women with polycystic ovary syndrome?
    Ricardo Azziz
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (3): : 132 - 133
  • [30] Bisphenol A analogues and metabolic syndrome in women with polycystic ovary syndrome
    Majewska, Joanna
    Berg, Andrzej
    Jurewicz, Joanna
    Owczarek, Katarzyna
    Zajdel, Rados law
    Kilanowicz, Anna
    Wasik, Andrzej
    Rachon, Dominik
    REPRODUCTIVE TOXICOLOGY, 2024, 123